18 completed, 12 terminated, 4 active not recruiting, 3 unknown. 41 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 18, Terminated 12, Active not recruiting 4, Unknown 3, Recruiting 2, Withdrawn 2 |
| Phase 1 | 11 | Terminated 5, Unknown 3, Completed 2, Active not recruiting 1 |
Follow rucaparib: new trials by email Literature Review of rucaparib trials Research Report on rucaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination Carboplatin, Paclitaxel, Bevacizumab - Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 1 / Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 290 | 2021-03-17 | 2021-08-27 |
| A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Rucaparib, Nivolumab - Leiomyosarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2020-11-05 | 2026-07-17 |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months AsiDNA, Niraparib, Olaparib - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 13 | 2020-10-05 | 2024-12-05 |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PLX038, Rucaparib, Ondansetron - Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2020-04-08 | 2026-08-26 |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Rucaparib, Copanlisib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Brown University | 13 | 2020-04-03 | 2025-05-04 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma Rucaparib, Ramucirumab, Nivolumab - Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma | Phase 1 / Phase 2 | Unknown | University of Kansas Medical Center | 34 | 2020-01-09 | 2023-02-01 |
| Rucaparib Maintenance Therapy in Advanced Cervical Cancer Rucaparib, Placebo - Cervical Cancer | Phase 2 | Withdrawn | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2019-10-01 | 2019-11-01 | |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma Rucaparib and Nivolumab - Small Cell Lung Cancer | Phase 2 | Completed | Zhonglin Hao | 33 | 2019-09-04 | 2024-10-22 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Rucaparib, Nivolumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | pharmaand GmbH | 1 | 2019-08-23 | 2023-06-12 |
| Pan Tumor Rollover Study Nivolumab, Ipilimumab, Cabozantinib - Cancer | Phase 2 | Recruiting | Bristol-Myers Squibb | 1500 | 2019-08-09 | 2026-10-30 |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Rucaparib, Bevacizumab, Atezolizumab - Endometrial Cancer, Uterine Carcinosarcoma | Phase 2 | Completed | Medical College of Wisconsin | 30 | 2019-07-19 | 2026-04-13 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | Terminated | pharmaand GmbH | 25 | 2019-06-28 | 2024-01-16 |
| Rucaparib in Nonmetastatic prOstAte With BRCAness Rucaparib - Prostate Cancer | Phase 2 | Terminated | University of Utah | 7 | 2019-05-20 | 2024-03-13 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Rucaparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 64 | 2019-04-16 | 2025-05-21 |
| Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors Atezolizumab, Rucaparib - Solid Tumor | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 130 | 2019-04-12 | 2025-12-01 |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Rucaparib, Nivolumab - Biliary Tract Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 32 | 2019-03-28 | 2025-06-03 |
| Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Rucaparib, Placebo Oral Tablet - Metastatic Endometrial Cancer | Phase 2 | Completed | University of Colorado, Denver | 79 | 2019-03-06 | 2026-03-24 |
| Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Rucaparib, Abemaciclib, pembrolizumab & bemcentinib - Mesothelioma, Malignant | Phase 2 | Completed | University of Leicester | 186 | 2019-01-28 | 2026-08-17 |
| Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Pembrolizumab, Pemetrexed, Carboplatin - Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 25 | 2018-12-24 | 2026-02-12 |
Showing 20 of 41. Sign in to see all of them.
Ovarian Neoplasms (8) · Fallopian Tube Neoplasms (6) · Breast Neoplasms (5) · Endometrial Neoplasms (5) · Prostatic Neoplasms (5) · Pancreatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Ovarian Epithelial (3) · Colorectal Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Transitional Cell (2) · Leiomyosarcoma (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2)
pharmaand GmbH (8) · Bristol-Myers Squibb (3) · Gustave Roussy, Cancer Campus, Grand Paris (2) · University of Michigan Rogel Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Academic and Community Cancer Research United (1) · Brown University (1) · Cancer Research UK (1) · Dana-Farber Cancer Institute (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Hoosier Cancer Research Network (1) · Incyte Corporation (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (31) · France (9) · United Kingdom (8) · Canada (6) · Spain (6) · Australia (5) · Germany (5) · Israel (5) · Italy (5) · Belgium (3) · Denmark (3) · Netherlands (3) · Argentina (2) · Brazil (2) · Chile (2)
Angel Qin, MD (1) · Anne Patsouris, MD (1) · Anwaar Saeed, MD (1) · Benedito Carneiro, MD, MS (1) · Bradley Corr, MD (1) · Dean Fennell, PhD, FRCP (1) · Domenica Lorusso, Prof. (1) · E.E. Voest, prof. (1) · Fred Zheng, MD, PhD (1) · Heather H. Cheng (1) · Heidi Giordano (1) · James Gulley, M.D. (1) · Jonathan W Riess (1)
PMID 35397664, PMID 25218906, PMID 31685558, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 12648575, PMID 14701743, PMID 15169803, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17714938, PMID 18024865, PMID 18268546, PMID 18955455, PMID 19049966, PMID 19553641, PMID 19779458, PMID 19826121, PMID 20551068, PMID 20606085, PMID 20609467, PMID 20609468, PMID 20620859, PMID 21205755, PMID 21537039, PMID 21720365, PMID 21862407, PMID 22203755, PMID 22204724, PMID 22204725, PMID 22237781
2018 (3), 2016 (2), 2017 (2), P30CA015083 (1), P30CA046934 (1), U10CA180888 (1)